Aslan partners with Array in its first development pact; deal expanded
Aslan Pharmaceuticals Pte. Ltd. (oncology, inflammation, and respiratory disease therapies) has licensed worldwide rights to Array BioPharma Inc.’s (cancer and inflammation) ARRY543, which is entering Phase II for solid tumors.
- Specialty Pharmaceuticals
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.